[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad de Guanajuato\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100621578","photobiomodulation-in-the-prevention-and-management-of-oral-mucositis-in-children-100621578",false,"NCT07372443","Photobiomodulation in the Prevention and Management of Oral Mucositis in Children","Usefulness of Photobio-modulation in the Prevention and Management of Oral Mucositis in Pediatric Patients Undergoing Antineoplastic Treatment: Randomized Clinical Trial","PBMOM-PEDMX","Inclusion Criteria:\n\nPrevention Arm - Inclusion Criteria\n\n* Age 4 to 17 years\n* Histopathologic diagnosis of malignant neoplasm: leukemia, lymphoma, or solid tumor of the head and neck.\n* Within days 1-3 of the start of any chemotherapy cycle; for leukemia patients, in consolidation phase as defined by protocol.\n* No signs of oral mucositis at enrollment.\n* Availability and willingness to attend scheduled photobiomodulation (PBM) application sessions.\n* Parent\u002Flegal guardian signed informed consent and child assent when applicable (≥ 8 years).\n* No documented primary immunodeficiency.\n* No severe concomitant systemic infection or medical condition that, in the investigator's judgment, contraindicates participation.\n* No PBM treatment within 14 days prior to enrollment.\n* No history of adverse reactions to light therapies or known photosensitivity.\n* No history of seizure disorder or diagnosis of epilepsy.\n\nTreatment Arm - Inclusion Criteria\n\n* Age 4 to 17 years\n* Histopathologic diagnosis of malignant neoplasm: leukemia, lymphoma, or solid tumor of the head and neck.\n* Currently receiving chemotherapy (any cycle of the regimen).\n* Presence of oral mucositis of any grade during chemotherapy, identified within the first 3 days from onset of the mucositis episode.\n* Parent\u002Flegal guardian signed informed consent and child assent when applicable (≥ 8 years).\n* No documented primary immunodeficiency.\n* No severe concomitant systemic infection or medical condition that, in the investigator's judgment, contraindicates participation.\n* No photobiomodulation (PBM) treatment within 14 days prior to enrollment.\n* No history of adverse reactions to light therapies or known photosensitivity.\n* No history of seizure disorder or diagnosis of epilepsy.\n\nExclusion Criteria:\n\n* Documented primary immunodeficiency.\n* Severe concomitant systemic infection or unstable medical condition.\n* PBM treatment within 14 days prior to enrollment.\n* Known photosensitivity or prior adverse reaction to light therapy.\n* History of seizures or epilepsy.\n* Any condition that, in the investigator's opinion, would interfere with study participation or safety.\n\nParticipant Withdrawal Criteria\n\n* Attendance to fewer than 80% of scheduled treatment sessions.\n* Any adverse event or persistent discomfort attributed to PBM that leads the participant or guardian to decline further intervention.\n* Withdrawal of consent by parent\u002Fguardian or assent withdrawal by participant when applicable.\n* Development of a new medical condition that, per investigator judgment, contraindicates continuation.","ALL","4 Years","17 Years",{"count":21,"type":22},49,"ESTIMATED","INTERVENTIONAL",[25],"NA","Oral mucositis (OM) is a frequent, debilitating complication in pediatric oncology that impairs quality of life, nutrition, hydration, and treatment adherence. This randomized, prospective, single blind trial in Mexico will evaluate photobiomodulation (PBM) versus a conventional bioadhesive gel for prevention and treatment of antineoplastic therapy-induced OM in children aged 4-17 with leukemia, lymphoma, or head and neck tumors. A total of 49 participants will be enrolled. The study has two components: (1) Treatment - parallel comparison of PBM versus bioadhesive gel for established OM; (2) Prevention - crossover design in which patients receive both interventions across successive chemotherapy cycles. PBM will be delivered with a 660 nm device, 40 mW, 10 J\u002Fcm². The primary outcome is OM grade by the WHO scale assessed on days 7, 11, 14, and 21. Expected results include reduced OM incidence, severity, duration, and pain with favorable safety and tolerability, supporting standardized PBM protocols in pediatric oncology in Mexico.",[28,29,30],"Oral Mucositis","Chemotherapy Effect","Pediatric Cancer",[32],"Photobiomodulation","NOT_YET_RECRUITING","2026-01-19",{"date":36,"type":37},"2026-01-28","ACTUAL",{"date":39,"type":22},"2026-01",{"date":41,"type":22},"2027-08",{"name":43,"class":44},"Universidad de Guanajuato","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100567360","phase-1-effects-of-low-intensity-transcranial-magnetic-stimulation-on-major-depressive-disorder-and-on-5-hydroxyindoleacetic-acid-and-brain-derived-neurotrophic-factor-levels-100567360","NCT06667180","Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels","Inclusion Criteria:\n\n* Age between 18 and 60 years.\n* Both sexes.\n* Those who have a diagnosis of MDD previously made by the treating psychiatrist (considering time since diagnosis and recurrence of episodes).\n* Those who continue with their respective treatment and attend follow-up consultations at the health facility.\n* Those who do not have a history of epilepsy, schizophrenia, neurosurgeries.\n* Those who do not have metal plates anywhere in the skull, neck, chest and shoulder.\n* Those who do not use pacemakers.\n* Those who do not take hormone substitutes.\n* Those who agree to participate in the research.\n\nExclusion Criteria:\n\n* Those who are pregnant.","18 Years","60 Years",{"count":54,"type":22},40,[56,57],"PHASE1","PHASE2","The goal of this randomised clinical trial is to evaluate the effects of transcranial magnetic stimulation (TMS) on major depressive disorder (MDD) and on the levels of 5-hydroxyindoleacetic acid (5-HIAA) and brain-derived neurotrophic factor (BDNF). TMS works to treat MDD by using low-intensity magnetic fields to modulate certain areas of the brain, activating them which can help improve the mood of those suffering from the disorder. Final metabolites of serotonin such as 5-HIAA and growth factors such as BDNF will also be studied before starting the intervention and at the end to check if there is a significant change in their concentration. Likewise, its safety will be evaluated by monitoring the symptoms that they present at the end of the intervention and one month later. The main questions that are intended to be answered are:\n\n* Does low-intensity TMS reduce depressive symptoms in patients with MDD?\n* Does low-intensity TMS significantly change the initial and final concentrations of 5-HIAA and BDNF?\n* What adverse effects might patients who are exposed to low-intensity TMS experience? The researchers will compare low-intensity and accelerated TMS with sham TMS to see if low-intensity TMS works to treat MDD.\n\nParticipants:\n\n* Will undergo an initial clinical assessment to confirm the disorder, comorbidities, and general health status.\n* A 5 mL blood sample will be taken before starting the intervention.\n* Low-intensity TMS will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 milliTesla (mT) and frequency of 50 Hz in theta bursts. Symptoms will be monitored daily.\n* A 5 mL blood sample will be taken at the end of the intervention and general health status clinimetrics will be reapplied.",[60,61,62],"Depression - Major Depressive Disorder","Transcranial Magnetic Stimulation","Placebo",[64,65,66,67,68],"accelerated low-intensity transcranial magnetic stimulation","Major depressive disorder","depression","brain-derived neurotrophic factor","5-hydroxyindoleacetic acid","RECRUITING","2025-05-05",{"date":72,"type":37},"2025-05-08",{"date":74,"type":37},"2024-10-28",{"date":76,"type":22},"2025-08-26",{"name":43,"class":44},1,""]